Beth Israel Deaconess Medical Center

5 of the latest cardiac tech insights out of ACC.21

The American College of Cardiology’s 70th Annual Scientific Session has produced some positive news about some controversial cardiac tech.

Drug-coated stents, which a 2018 study linked to late-stage death, were shown to be non-inferior to non-drug-coated stents in patients with peripheral arterial disease. And a new study of renal denervation that used a different methodology showed significant progress in reducing high blood pressure.

Get the full story on our sister site, Medical Design & Outsourcing.

Medtronic appoints new VP & CMO for coronary, renal denervation & structural heart

Medtronic (NYSE:MDT) announced that it appointed Dr. Jeffrey Popma as its new VP and chief medical officer for coronary, renal denervation and structural heart business.

Popma, a professor of medicine at Harvard Medical School and director of interventional cardiology at Beth Israel Deaconess Medical Center in Boston, is slated to provide medical leadership across those businesses, serve as a strategic advisor for cardiovascular device innovation and help to develop a clinical research portfolio, according to a news release.

He is set to assume the role on June 22 and report to Nina Goodheart, president of the coronary & structural heart division as part of the cardiac and vascular group.

“I am honored to be joining Medtronic to help deliver on its enduring Mission of patient-focused medical device innovation,” Popma said in the release. “I look forward to collaborating with the talented cardiovascular and structural heart teams at Medtro…